VIR stock forecast, quote, news & analysis
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer... Show more
Why Vir Biotechnology (VIR) Stock Is Down -12.8% in the Last 30 Days
Key Takeaways
- Vir Biotechnology (VIR) shares declined approximately 12.8% over the last 30 days, falling from $10.19 on June 30, 2026, to $8.89 as of July 30, 2026.
- The departure of CFO Jason O'Byrne and the appointment of an interim financial officer in late July weighed heavily on investor sentiment.
- Broader quarterly performance reflects a challenging post-earnings environment following a significant Q1 2026 earnings miss reported in early May.
- Positive clinical catalysts, including Week 96 SOLSTICE trial data in hepatitis delta presented at the EASL Congress, temporarily lifted shares in June before July's selloff.
- Analyst consensus remains a Moderate Buy with a $20.88 average price target, though mixed ratings and insider selling activity have added to near-term uncertainty.
Vir Biotechnology (VIR) Company Overview and Market Position
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on harnessing the immune system to develop therapies for serious infectious diseases and cancer. Headquartered in San Francisco, the company's clinical-stage pipeline includes programs targeting chronic hepatitis delta and multiple PRO-XTEN dual-masked T-cell engagers across validated targets in solid tumor indications. Vir also maintains a preclinical portfolio spanning infectious diseases and oncologic malignancies. The company holds exclusive rights to the PRO-XTEN masking platform for oncology and infectious disease applications. Investors closely follow Vir for its differentiated immunology approach, its partnership activity—including a global agreement with ALPMY (Astellas) in prostate cancer—and the progress of its hepatitis delta program, which represents one of the most advanced clinical candidates in a disease area with significant unmet medical need.
Vir Biotechnology (VIR) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Vir Biotechnology shares fell from a closing price of $10.19 on June 30, 2026, to $8.89 on July 30, 2026, representing a decline of approximately 12.8%. The downward move was not linear: the stock held above $10 through the first week of July, touching a high of $10.58 intraday on July 9, before persistent selling pressure drove shares steadily lower. A sharp single-day drop occurred on July 24, when the stock fell from $9.34 to $8.69 following the CFO transition announcement.
Looking at the full quarter, the stock has declined roughly 13% from $10.22 at the end of April 2026. The quarterly journey has been volatile. Shares tumbled in mid-May after the Q1 2026 earnings report showed a substantial miss on both top and bottom lines, bottoming near $8.25 by June 10. A mid-June rebound fueled by positive clinical data and analyst upgrades pushed the stock back above $10.30, but those gains have now been fully erased. The overall quarterly pattern reveals a stock struggling to sustain upward momentum amid mixed fundamental and leadership signals.
What Drove VIR Stock Price in the Last 30 Days
The most significant catalyst during the past 30 days was the July 24 announcement that CFO Jason O'Byrne is departing the company. Brent Sabatini, Senior Vice President and Chief Accounting Officer, was appointed Interim Principal Financial Officer while the company conducts a search for a permanent successor. CFO departures at clinical-stage biotech companies frequently trigger investor concern about financial stability and strategic continuity, and VIR's share price reaction reflected that dynamic with a pronounced single-day decline.
Additionally, the company announced on July 22 that it will host its Q2 2026 earnings conference call on August 5. Pre-earnings positioning may be contributing to cautious trading, particularly following the sizable Q1 2026 miss, where Vir reported an EPS of ($0.85) against consensus estimates of ($0.01) and revenue that fell drastically short of the expected $55.49 million. The memory of that miss likely continues to influence investor sentiment heading into the upcoming report.
Insider selling activity has also been a factor. Director Vicki L. Sato sold 22,000 shares at an average price of $10.05 in May, and Director Janet Napolitano sold 3,200 shares at $9.45 in June—both executed under pre-arranged Rule 10b5-1 trading plans. While such plans are established in advance, the optics of insider sales during a period of stock price weakness can contribute to cautious market sentiment.
What Drove VIR Stock Performance Over the Last Quarter
The broader quarterly narrative has been shaped by a tug-of-war between disappointing fundamentals and promising pipeline progress. On May 6, Vir reported Q1 2026 financial results that missed consensus estimates by a wide margin, triggering an immediate selloff that sent shares from around $10.29 to $9.27 in a single session. The stock continued to drift lower over the following weeks, reaching approximately $8.25 by June 10.
Momentum reversed sharply in mid-June following the presentation of complete Week 96 data from the Phase 2 SOLSTICE clinical trial evaluating tobevibart and elebsiran for chronic hepatitis delta at the EASL Congress 2026 in Barcelona. The positive data reinforced the therapeutic potential of Vir's hepatitis delta program and sparked a rally that carried shares as high as $10.38 by June 29. Supporting the bullish case, Morgan Stanley raised its price target from $23 to $27 with an Overweight rating on June 11, and Leerink Partners lifted its target from $20 to $21 with an Outperform rating on June 3. The appointment of Timothy Coughlin to the Board of Directors in early June was viewed as a governance positive. However, the July CFO transition and upcoming Q2 earnings uncertainty ultimately overwhelmed these positive developments, resulting in the stock's retreat below $9.
Trending AI Robots
For investors seeking data-driven, automated approaches to navigating stocks like Vir Biotechnology, Tickeron's Trending AI Robots page offers a curated view of top-performing AI trading bots. Tickeron hosts hundreds of AI-powered trading bots that collectively trade thousands of tickers across diverse strategies and timeframes. Only the most relevant and consistently high-performing bots are featured in the Trending section, making it a practical starting point for traders who want to explore algorithmic strategies without sifting through the entire bot marketplace. Each bot is designed with distinct parameters—some focus on short-term momentum, while others emphasize longer-duration swing trades or trend-following approaches. Browsing the Trending AI Robots page can help users identify strategies that align with their own trading objectives and risk tolerance.
VIR Stock Forecast Drivers: What Investors Should Watch Next
The most immediate catalyst is the Q2 2026 earnings report and corporate update scheduled for August 5. Investors will scrutinize revenue figures, EPS, cash position, and forward guidance for any signs of stabilization following the Q1 miss. Commentary on the Astellas prostate cancer collaboration, which closed in April, and updates on the chronic hepatitis delta program's regulatory path will be closely watched. The CFO search timeline and any additional leadership changes could further influence sentiment. From an analyst perspective, the wide gap between the current stock price near $8.89 and the consensus price target of $20.88 suggests that the market is pricing in significant execution risk. Macroeconomic factors affecting the biotech sector—including interest rate expectations and risk appetite for pre-revenue clinical-stage companies—remain relevant. Competitive developments in the hepatitis delta and T-cell engager spaces, as well as any partnership or licensing announcements, could also serve as meaningful catalysts in either direction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for VIR turns positive, indicating new upward trend
VIR saw its Momentum Indicator move above the 0 level on August 07, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 57 cases where VIR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for VIR just turned positive on August 11, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in of 260 cases, the price rose further within the following month. The odds of a continued upward trend are .
VIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
VIR moved below its 50-day moving average on July 24, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VIR crossed bearishly below the 50-day moving average on July 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for VIR entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.550) is normal, around the industry mean (20.281). P/E Ratio (0.000) is within average values for comparable stocks, (25.508). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.845). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (4.413) is also within normal values, averaging (437.072).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases
Industry Biotechnology